Skip to main content

Table 2 Summary Baseline Demographic and Clinical Characteristics of REVITAHIP Participantsa

From: An initial loading-dose vitamin D versus placebo after hip fracture surgery: randomized trial

Variables

Active (n = 111)

Placebo (n = 107)

P value

Sex – n (%)

   

 - Female

84 (75.7)

84 (78.5)

0.633

 - Male

27 (24.3)

23 (21.5)

Country of Birth – n (%)

   

 - Australia

92 (82.9)

86 (80.4)

0.727

 - Other

19 (17.1)

21 (19.6)

Age

   

 Mean (years)b

83.7+/−7.5

84.1+/−7.0

0.726

 Grouped – n (%)

   

  - 65-74 yr

15 (13.5)

10 (9.3)

0.772

  - 75-84 yr

43 (38.7)

42 (39.3)

  - 85-94 yr

47 (42.3)

50 (46.7)

  - 95+ yr

6 (5.4)

5 (4.7)

Body mass index (kg/m2)b

24.2+/−3.4

25.1+/−3.8

0.099

Number of days from admission to loading doseb

4.8+/−2.1

5.4+/−2.3

0.049

Pre-injury mobility – n (%)d

   

 - Fully independent

80 (72.1)

72 (67.9)

0.156

 - Minimum help

15 (13.5)

15 (14.2)

 - Moderately help

8 (7.2)

7 (6.6)

 - Substantial help

1 (0.9)

8 (7.5)

 - Unable to perform task

7(6.3)

4(3.8)

Pre-injury Modified Barthel index

87.5+/−19.9

86.9+/−22.2

0.852

Pre-injury Functional Comorbidity Index b

3.37+/−2.1

2.9+/−1.7

0.063

Hip Fracture Subtype – n (%)d

   

 - Undisplaced subcapital

6 (5.7)

3 (2.8)

0.442

 - Displaced subcapital:

50 (47.2)

48 (45.3)

 - Pertrochanteric simple (2-part)

5 (4.7)

5 (4.7)

 - Pertrochanteric complex (3-part)

27 (25.5)

34 (21.1)

 - Intertrochanteric/basicervical

5 (4.7)

9 (8.5)

 - Subtrochanteric

13 (12.3)

7 (6.6)

Time from fracture to surgery (in hours)b

43.8+/−38.9

38.9+/−25.9

0.272

Hip Fracture Surgeryd

  

0.655

 - Cannulated screws

4 (3.7)

1 (0.9)

 - Uncemented hemiarthroplasty

15 (14.0)

14 (13.2)

 - Cemented hemiarthroplasty

8 (7.5)

9 (8.5)

 - Total hip replacement

19 (17.8)

20 (18.9)

 - Dynamic hip screw with short plate

14 (13.1)

8 (7.5)

 - Dynamic hip screw with long plate

19 (17.8)

20 (18.9)

 - Gamma nail

28 (26.2)

34 (32.1)

MMSE score (mean, standard deviation)b

26.32+/−4.3

25.7+/−4.4

0.282

Total number of medications usedb

5.1+/−2.6

4.9+/−2.6

0.201

25-hydroxyvitamin D level (nmol/L)c

   

 Mean

55.6+/−26.4

49.6+/−19.7

0.112

 Grouped values: n (%)e

   

  - <30

13 (16.5)

11 (14.3)

0.621

  - 30-49

22 (27.8)

27 (35.1)

 

  - > = 50

44 (55.7)

39 (50.6)

 

Grip strength (kgs)b

16.4+/−7.3

15.7+/−6.2

0.478

  1. aPlus-minus values are means +/− SD
  2. bContinuous variables were compared with the use of a two-sample t-test. Categorical variables were compared with the use of a chi-square test
  3. cFor participants given the intervention loading dose after 25-OHD levels were taken (n = 156), (Placebo = 77; Active = 79)
  4. dThe following categories contained missing variables: hip fracture subtype (6 missing, n = 212), hip fracture surgery (6 missing, n = 212), premorbid mobility (1 missing, n = 217)
  5. eNowson CA, McGrath JJ, Ebeling PR, Haikerwal A, Daly RM, Sanders KM, Seibel MJ, Mason RS; Working Group of Australian and New Zealand Bone and Mineral Society, Endocrine Society of Australia and Osteoporosis Australia. Vitamin D and health in adults in Australia and New Zealand: a position statement. Med J Aust. 2012;196(11):686–7 [25]